Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin
暂无分享,去创建一个
J. A. Spicer | W. Denny | J. Trapani | D. Lyons | I. Voskoboinik | N. Helsby | S. Jamieson | K. Browne | G. Lena | K. Huttunen | Patrick D. O’Connor | M. Bull | Jamie Lopez | A. Ciccone | Christian K. Miller | J. Rudd-Schmidt | Matthew R. Bull
[1] J. Trapani,et al. Rapid and Unidirectional Perforin Pore Delivery at the Cytotoxic Immune Synapse , 2013, The Journal of Immunology.
[2] Helen R Saibil,et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. , 2013, Blood.
[3] Jonathan B. Baell,et al. Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350, 000 Compounds , 2013, J. Chem. Inf. Model..
[4] J. Whisstock,et al. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. , 2012, Trends in immunology.
[5] T. Tomašič,et al. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation , 2012, Expert opinion on drug discovery.
[6] J. A. Spicer,et al. Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones. , 2012, Bioorganic & medicinal chemistry.
[7] Thomas Mendgen,et al. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. , 2012, Journal of medicinal chemistry.
[8] M. Gütschow,et al. New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. , 2011, Bioorganic & medicinal chemistry.
[9] J. A. Spicer,et al. Inhibition of the cellular function of perforin by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles. , 2011, Bioorganic & medicinal chemistry.
[10] Olivia Susanto,et al. Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. , 2011, Immunity.
[11] L. Meijer,et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. , 2011, Journal of medicinal chemistry.
[12] K. Kinzler,et al. Thiazolidinedione-Based PI3Kα Inhibitors: An Analysis of Biochemical and Virtual Screening Methods , 2011, ChemMedChem.
[13] J. Whisstock,et al. The structural basis for membrane binding and pore formation by lymphocyte perforin , 2010, Nature.
[14] A. Fischer,et al. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules , 2010, Nature Reviews Immunology.
[15] Yong-tang Zheng,et al. Anti HIV-1 agents 5: synthesis and anti-HIV-1 activity of some N-arylsulfonyl-3-acetylindoles in vitro. , 2010, Bioorganic & medicinal chemistry letters.
[16] J. Whisstock,et al. Perforin: structure, function, and role in human immunopathology , 2010, Immunological reviews.
[17] J. Trapani,et al. The role of perforin and granzymes in diabetes , 2010, Cell Death and Differentiation.
[18] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[19] J. Trapani,et al. The battlefield of perforin/granzyme cell death pathways , 2010, Journal of leukocyte biology.
[20] J. Whisstock,et al. The molecular basis for perforin oligomerization and transmembrane pore assembly. , 2009, Immunity.
[21] T. Tomašič,et al. Rhodanine as a privileged scaffold in drug discovery. , 2009, Current medicinal chemistry.
[22] J. A. Spicer,et al. Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin. , 2008, Journal of medicinal chemistry.
[23] Ashley M Buckle,et al. A Common Fold Mediates Vertebrate Defense and Bacterial Attack , 2007, Science.
[24] I. Yaniv,et al. Pancreatic islets under attack: cellular and molecular effectors. , 2007, Current pharmaceutical design.
[25] G. Janka. Familial and acquired hemophagocytic lymphohistiocytosis , 2006, European Journal of Pediatrics.
[26] J. Tredger,et al. Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management , 2006, Pediatric transplantation.
[27] R. Kiesslich,et al. Drug Insight: novel small molecules and drugs for immunosuppression , 2006, Nature Clinical Practice Gastroenterology &Hepatology.
[28] D. Gjertson,et al. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. , 2006, Human immunology.
[29] A. Chakraborti,et al. Copper(II) tetrafluoroborate as a novel and highly efficient catalyst for acetal formation , 2005 .
[30] A. Mori,et al. Palladium-catalyzed coupling reactions of bromothiophenes at the C-H bond adjacent to the sulfur atom with a new activator system, AgNO3/KF. , 2005, Organic letters.
[31] B. McManus,et al. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. , 2004, The American journal of pathology.
[32] Mark J. Smyth,et al. Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.
[33] R. Bleackley,et al. Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.
[34] G. Gribble,et al. A synthesis of 6,11-disubstituted benzo[b]carbazoles , 2001 .
[35] J. Trapani,et al. Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.
[36] A. Fischer,et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.
[37] Xiaojun Wang,et al. A significantly improved condition for cyclization of phenethylcarbamates to N-alkylated 3,4-dihydroisoquinolones , 1998 .
[38] R. Zinkernagel,et al. Reduced Incidence and Delayed Onset of Diabetes in Perforin-deficient Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.
[39] Ta‐Jung Lu,et al. An Efficient Method for the Acetalization of α,β- Unsaturated Aldehydes. , 1995 .
[40] Ta‐Jung Lu,et al. An Efficient Method for the Acetalization of .alpha.,.beta.-Unsaturated Aldehydes , 1995 .
[41] C. Humblet,et al. Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists. , 1992, Journal of medicinal chemistry.
[42] P. Lu,et al. Structure and function of human perforin , 1988, Nature.
[43] E. Podack. Perforin: structure, function, and regulation. , 1992, Current topics in microbiology and immunology.